Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.

Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.

The manufacturing-units of Aarti Drugs Ltd. are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.

The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery.

Business area of the company

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited.

Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

Aarti Drugs Ltd.

Hikal Ltd.

FDC Ltd.

Indoco Remedies Ltd.

Wockhardt Ltd.

Glenmark Life Sciences Ltd.

AMI Organics Ltd.

Advanced Enzyme Technologies Ltd.

Unichem Laboratories Ltd.

Caplin Point Laboratories Ltd.

Strides Pharma Science Ltd.

Jubilant Pharmova Ltd.

Shilpa Medicare Ltd.

Sequent Scientific Ltd.

Marksans Pharma Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	4,266 Cr		EPS	18.6		High	456.15
Stock P/E	24.8		Net Profit Margin	5.6		Low	450.2

Open Price	450.45	Volume	929
Prev. Close	463.55

AARTIDRUGS